Canada Approves First Generic Version Of Ozempic By Dr. Reddy’s

Dr. Reddy’s Laboratories has received regulatory clearance in Canada to launch a generic version of Ozempic, a widely prescribed drug for type 2 diabetes. The move is expected to enhance accessibility and affordability while strengthening the company’s global footprint.  

Approval Details  

Health Canada granted approval for Dr. Reddy’s generic semaglutide injection, making it the first alternative to Novo Nordisk’s blockbuster drug in the Canadian market. The product will be available under strict quality and safety standards.  

Market Impact  

Ozempic has seen surging demand globally, not only for diabetes management but also for weight control. The entry of a generic version is expected to reduce costs and increase competition, benefiting patients and healthcare systems.  

Strategic Outlook  

For Dr. Reddy’s, this approval reinforces its strategy of expanding into regulated markets with high-demand therapies. Analysts believe the launch could significantly boost revenues and strengthen its position in the global generics industry.  

Key Highlights  

• Canada approves first generic Ozempic  
• Dr. Reddy’s Laboratories secures regulatory clearance  
• Generic semaglutide to lower treatment costs  
• Increased competition in diabetes care market  
• Strategic boost for Dr. Reddy’s global expansion  

Sources: Reuters, Bloomberg News, Economic Times